Cristea MC, Stewart D, Synold T, Ruel N, et al. A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRalpha-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer. Gynecol Oncol 2024;182:124-131.
PMID: 38262235